Evaluation of infections in the lung transplant patient

Current Opinion in Infectious Diseases

Volumn 25, Issue 2, 2012, Pages 193-198

  Watkins, Richard R ^a,b   Lemonovich, Tracy L ^c  

^a AKRON GENERAL MEDICAL CENTER   (United States)

^b Northeastern Ohio Medical University   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Aspergillus; cytomegalovirus; lung transplantation; mycobacteria; pneumonia; Pseudomonas; Staphylococcus aureus

Indexed keywords

AZITHROMYCIN; BENZIMIDAVIR; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; VALGANCICLOVIR; VANCOMYCIN;

ANTIVIRAL RESISTANCE; ASPERGILLUS; BACTERIAL COLONIZATION; BRONCHIOLITIS OBLITERANS; CLINICAL EVALUATION; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DEATH; DIAGNOSTIC TEST; DRUG EFFECT; FUNGAL COLONIZATION; GENOTYPE; GRAFT RECIPIENT; HUMAN; LUNG INFECTION; LUNG TRANSPLANTATION; MORTALITY; MYCOBACTERIUM ABSCESSUS; NONHUMAN; PATHOGENESIS; PRACTICE GUIDELINE; PREOPERATIVE COMPLICATION; REVIEW; RISK FACTOR; RNA INTERFERENCE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANTI-INFECTIVE AGENTS; HUMANS; LUNG TRANSPLANTATION; RESPIRATORY TRACT INFECTIONS; RISK FACTORS;

EID: 84858005885     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32834c54bc     Document Type: Review

References (43)

1. Christie JD, Edwards LB, Aurora P, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart/lung transplantation report-2008. J Heart Lung Transplant 2008; 27:957-969.
2. Sims KD, Blumberg EA. Common infections in the lung transplant recipient. Clin Chest Med 2011; 32:327-341. A well written review paper on infections in LTRs including recommendations about screening tests and vaccines.
3. Verleden GM, Vos R, van Raemdonck D, Vanaudenaerde B. Pulmonary infection defense after lung transplantation: does airway ischemia play a role? Curr Opin Organ Transplant 2010; 15:568-571.
4. Kovats Z, Sutto Z, Murakozy G, et al. Airway pathogens during the first year after lung transplantation: a single-center experience. Transplant Proc 2011; 43:1290-1291.
5. Aaron SD, Vandemheen KL, Ramotar K, et al. Infection with transmissible strains of Pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis. JAMA 2010; 304:2145-2153.
6. Nash EF, Coonar A, Kremer R, et al. Survival of Burkholderia cepacia sepsis following lung transplantation in recipients with cystic fibrosis. Transpl Infect Dis 2010; 12:551-554.
7. Bode LG, Kluytmans JA, Wertheim HF, et al. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med 2010; 362:9-17.
8. Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 2010; 23:299-323.
9. Chalermskulrat W, Sood N, Neuringer IP, et al. Nontuberculosis mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 2006; 61:507-513. (Pubitemid 43901521)
10. Morales P, Gil A, Santos M. Mycobacterium abscessus infection in transplant recipients. Transplant Proc 2010; 42:3058-3060.
11. Luong ML, Morrissey O, Husain S. Assessment of infectious risks prior to lung transplantation. Curr Opin Infect Dis 2010; 23:578-583.
12. Nishi SPE, Valentine VG, Duncan S. Emerging bacterial, fungal, and viral respiratory infections in transplantation. Infect Dis Clin N Am 2010; 24:541-555.
13. Eid AJ, Razonable RR. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 2010; 70:965-981.
14. Mitsani D, Nguyen MH, Kwak EJ, et al. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis. J Heart Lung Transplant 2010; 29:1014-1020.
15. Lefeuvre S, Chevalier P, Charpentier C, et al. Valganciclovir prophylaxis for cytomegalovirus infection in thoracic transplant patients: retrospective study of efficacy, safety, and drug exposure. Transpl Infect Dis 2010; 12:213-219. This study demonstrates that valganciclovir is well tolerated and effective in preventing CMV disease in LTRs.
16. Miller S, Seet H, Khan Y, et al. Comparison of QUIAGEN automated nucleic acid extraction methods for CMV quantitative PCR testing. Am J Clin Pathol 2010; 133:558-563.
17. Snydman DR, Limaye AP, Potena L, et al. Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant Proc 2011; 43:S1-S17.
18. Parada MT, Alba A, Sepulveda C. Bronchiolitis obliterans syndrome development in lung transplantation patients. Transplant Proc 2010; 42:331-332.
19. Shah PD, McDyer JF. Viral infections in lung transplant recipients. Semin Respir Crit Care Med 2010; 31:243-254.
20. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network. Clin Infect Dis 2010; 50:1101-1111. This study provides an update on notable changes in the epidemiology of opportunistic fungal infections in LTRs.
21. Eriksson M, Lemstrom K, Suojaranta-Ylinen R, et al. Control of early Aspergillus mortality after lung transplantation: outcome and risk factors. Transplant Proc 2010; 42:4459-4464.
22. Hosseini-Moghaddam SM, Husain S. Fungi and molds following lung transplantation. Semin Respir Crit Care Med 2010; 31:222-233.
23. Carneiro HA, Coleman JJ, Restrepo A, Mylonakis E. Fusarium infection in lung transplant patients. Medicine 2011; 90:69-80.
24. Huang HC, Weigt SS, Derhovanessian A, et al. Nontuberculosis mycobacterium infection after lung transplantation is associated with increased mortality. J Heart Lung Transplant 2011; 30:790-798.
25. Weinberg A, Lyu DM, Li S, et al. Incidence and morbidity of human meta-pneumovirus and other community-acquired respiratory viruses in lung transplant recipients. Transpl Infect Dis 2010; 12:330-335.
26. Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP. The diagnostic value of halo and reverse halo signs for invasive mold infections in compromised hosts. Clin Infect Dis 2011; 52:1144-1155.
27. Vos R, Vanaudenaerde BM, Verleden SE, et al. Diagnostic value of antibodies against Pseudomonas aeruginosa in bronchoalveolar lavage fluid after lung transplantation. Transplant Proc 2010; 42:4415-4420.
28. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89:779-795. These guidelines provide updated recommendations for the diagnosis and treatment of CMV disease in solid organ transplant recipients.
29. Kotloff RM, Thabut G. Lung transplantation. Am J Respir Crit Care Med 2011; 184:159-171.
30. Kumar D, Husain S, Chen MH, et al. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation 2010; 89:1028-1033.
31. Hauser PM, Bille J, Lass-Florl C, et al. Multicenter, prospective clinical evaluation of respiratory samples from subjects at risk for Pneumocystis jiroveci infection by use of a commercial real-time PCR assay. J Clin Microbiol 2011; 49:1872-1878.
32. Husain S, Kwak EJ, Obman A, et al. Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 2004; 4:796-802. (Pubitemid 38637580)
33. Husain S, Paterson DL, Studer SM, et al. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant patients. Transplantation 2007; 83:1330-1336. (Pubitemid 46800308)
34. Luong ML, Clancy CL, Vadnerkar A, et al. Comparison of an Aspergillus realtime polymerase chain reaction assay with galactomannan testing of bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in lung transplant recipients. Clin Infect Dis 2011; 52:1218-1266.
35. Alexander BD, Smith PB, Davis RD, et al. The (1,3){beta}-D-glucan test as an aid to early diagnosis of invasive infections following lung transplantation. J Clin Microbiol 2010; 48:4083-4088.
36. Jain R, Hachen RR, Morrell MR, et al. Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. J Heart Lung Transplant 2010; 29:531-537.
37. Vos R, Vanaudenaerde BM, Ottevaere A, et al. Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer? J Heart Lung Transplant 2010; 29:1358-1368.
38. Hays D, Murphy BS, Mullett TW, Feola DJ. Aerosolized vancomycin for the treatment of MRSA after lung transplantation. Respirology 2010; 15:182-186.
39. Monforte V, Ussetti P, Gavalda J, et al. Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation. J Heart Lung Transplant 2010; 29:523-530.
40. Lischka P, Hewlett G, Wungerg T, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother 2010; 54:1290-1297.
41. Avery RK, Marty FM, Strasfeld L, et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis 2010; 12:489-496.
42. Razonable RR. Immune-based therapies for cytomegalovirus infection. Immunotherapy 2010; 2:117-130.
43. Zamora MR, Budev M, Rolfe M, et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med 2011; 183:531-538. This study is the first randomized trial of an antiviral drug in RSV-infected LTRs.